Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and thank you for standing by. My name is Mark and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Vanta Pharmaceuticals Inc. earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. And to withdraw your question, press star one again. Now I would like to turn the call over to Kevin Moran. Vandas Chief Financial Officer, please go ahead. Thank you, Mark. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceutical's third quarter 2025 performance. Our third quarter 2025 results were released this afternoon and are available on the SEC's editor system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mahalis Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Tim Williams, our General Counsel. Following my introductory remarks, Mahalis will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's...